Virtus ETF Advisers’s Xeris Biopharma Holdings XERS Stock Holding History

Virtus ETF Advisers’s Portfolio XERS Stock Details XERS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-20,910	Closed	-$70.9K	–	805
2024 Q4	$70.9K	Buy	+20,910	New	+$67.3K	0.03%	366

Other funds holding XERS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Virtus ETF Advisers's XERS Position: Q1 2025 in Review

Virtus ETF Advisers sold out of Xeris Biopharma Holdings (XERS) in Q1 2025, closing a stake of 20,910 shares — an estimated $70.9K sold.

Virtus ETF Advisers first reported a position in XERS in Q4 2024 and held it in 1 quarter. The position peaked at $70.9K in Q4 2024. 199 funds tracked by Wall St. Rank hold XERS as of Q1 2025.

Virtus ETF Advisers reported no remaining Xeris Biopharma Holdings position as of Q1 2025 after selling out during the quarter.
Virtus ETF Advisers sold 20,910 Xeris Biopharma Holdings shares in Q1 2025, an estimated $70.9K.
Virtus ETF Advisers first reported a position in Xeris Biopharma Holdings in Q4 2024 and held it in 1 quarter.
Virtus ETF Advisers's Xeris Biopharma Holdings position peaked at $70.9K in Q4 2024.
199 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q1 2025.

Based on Virtus ETF Advisers's 13F filing for Q1 2025, filed 14 May 2025.